Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Net Income: 2020-2023

Historic Net Income for Therapeutics (RAPT) over the last 4 years, with Dec 2023 value amounting to -$33.2 million.

  • Therapeutics' Net Income fell 35.96% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 48.10%. This contributed to the annual value of -$127.1 million for FY2023, which is 48.10% down from last year.
  • Therapeutics' Net Income amounted to -$33.2 million in Q4 2023, which was up 2.07% from -$33.9 million recorded in Q3 2023.
  • In the past 5 years, Therapeutics' Net Income registered a high of -$12.4 million during Q2 2020, and its lowest value of -$33.9 million during Q3 2023.
  • Moreover, its 3-year median value for Net Income was -$21.2 million (2022), whereas its average is -$23.5 million.
  • Data for Therapeutics' Net Income shows a maximum YoY crashed of 56.47% (in 2023) over the last 5 years.
  • Over the past 4 years, Therapeutics' Net Income (Quarterly) stood at -$12.7 million in 2020, then plummeted by 40.79% to -$17.9 million in 2021, then tumbled by 36.27% to -$24.4 million in 2022, then tumbled by 35.96% to -$33.2 million in 2023.
  • Its last three reported values are -$33.2 million in Q4 2023, -$33.9 million for Q3 2023, and -$28.4 million during Q2 2023.